Singapore, 16 September 2010 – Biosensors International Group, Ltd. (“Biosensors” or the “Company”, Bloomberg: BIG SP) announced today that it has received CE Mark approval for both 33mm and 36mm lengths of its BioMatrix Flex™ drug-eluting stent (DES) system, further expanding the currently available range of 8mm to 28mm lengths. Both longer lengths of stent are available in diameters ranging from 2.50mm to 3.50mm.
These new additions to the BioMatrix Flex portfolio offer a significant opportunity to increase market penetration, as an estimated 15 percent of all DES usage involves long lengths.
“We have been very encouraged by the uptake of our latest addition to the BioMatrix stent family since its launch in May of this year”, commented President and CEO Jeffrey B. Jump. “We anticipate that the availability of BioMatrix Flex in these longer lengths will further enhance our penetration of the global DES market”.
The BioMatrix Flex drug-eluting stent received CE Mark approval in January 2010 and is currently available in major European, Middle East and African markets, as well as in selected Asian markets.
The BioMatrix Flex stent combines the proven combination of Biosensors’ unique biodegradable polymer technology with an improved mechanical platform for enhanced deliverability. The new stent platform combines a curved strut connector with the established Quadrature Link™ design of the existing BioMatrix platform, improving flexibility and trackability, while ensuring stent security and vessel scaffolding. A larger initial cell opening than the original also improves side branch accessibility
Posts
Bitcoin slides below US$60,000 on reports Israel strikes Iran
-
CRYPTOCURRENCIES fell heavily and bitcoin broke below US$60,000 on Friday
in a rush out of risky assets following reports of an Israeli missile
strike on I...
1 hour ago
No comments:
Post a Comment